stoxline Quote Chart Rank Option Currency Glossary
  
Eloxx Pharmaceuticals, Inc. (ELOX)
0.8  0.055 (7.38%)    06-13 14:36
Open: 0.62
High: 0.8
Volume: 4,124
  
Pre. Close: 0.745
Low: 0.62
Market Cap: 3(M)
Technical analysis
2024-06-13 4:42:59 PM
Short term     
Mid term     
Targets 6-month :  0.99 1-year :  1.16
Resists First :  0.84 Second :  1
Pivot price 0.75
Supports First :  0.6 Second :  0.5
MAs MA(5) :  0.7 MA(20) :  0.77
MA(100) :  0.87 MA(250) :  2.42
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  37.7 D(3) :  21.4
RSI RSI(14): 50.9
52-week High :  10.5 Low :  0.4
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ELOX ] has closed below upper band by 33.7%. Bollinger Bands are 0.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.8 - 0.8 0.8 - 0.81
Low: 0.61 - 0.62 0.62 - 0.62
Close: 0.79 - 0.8 0.8 - 0.81
Company Description

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Headline News

Wed, 13 Mar 2024
Healthcare Stocks Moving Up and Down Wednesday: HRTX, ELOX, CRDF, CUE, TNON, TSVT, WORX, ADCT - InvestorsObserver

Wed, 13 Mar 2024
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological ... - Business Wire

Tue, 11 Jul 2023
Top Penny Stocks Today? Why ELOX Stock Is Skyrocketing & 3 More To Watch - Penny Stocks

Wed, 21 Jun 2023
Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome - Yahoo Finance

Tue, 06 Jun 2023
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities ... - Yahoo Finance

Tue, 16 May 2023
Why Is Eloxx Pharmaceuticals (ELOX) Stock Down 27% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 3 (M)
Shares Float 3 (M)
Held by Insiders 0.4 (%)
Held by Institutions 15.6 (%)
Shares Short 21 (K)
Shares Short P.Month 34 (K)
Stock Financials
EPS -8.89
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -6.54
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -73.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -6.13
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -8 (M)
Stock Valuations
PE Ratio -0.1
PEG Ratio 0
Price to Book value -0.13
Price to Sales 0
Price to Cash Flow -0.14
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android